• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of azathioprine in IBD: modern aspects of an old drug.

作者信息

Louis Edouard, Irving Peter, Beaugerie Laurent

机构信息

Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium.

Department of Gastroenterology, Guy's & St Thomas' NHS Foundation Trust, London, UK.

出版信息

Gut. 2014 Nov;63(11):1695-9. doi: 10.1136/gutjnl-2013-306711. Epub 2014 Jun 18.

DOI:10.1136/gutjnl-2013-306711
PMID:24943205
Abstract
摘要

相似文献

1
Use of azathioprine in IBD: modern aspects of an old drug.硫唑嘌呤在炎症性肠病中的应用：一种老药的现代进展
Gut. 2014 Nov;63(11):1695-9. doi: 10.1136/gutjnl-2013-306711. Epub 2014 Jun 18.
2
[Azathioprine in inflammatory bowel disease].[硫唑嘌呤在炎症性肠病中的应用]
Acta Med Port. 2009 Jan-Feb;22(1):33-40. Epub 2009 Mar 25.
3
Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.预测炎症性肠病患儿初诊时对硫唑嘌呤的需求。
J Pediatr Gastroenterol Nutr. 2008 Aug;47(2):123-9. doi: 10.1097/MPG.0b013e318156a834.
4
Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.儿童炎症性肠病的免疫抑制治疗：北美儿科胃肠病学与营养学会的一项调查结果。儿科炎症性肠病协作研究论坛免疫抑制应用小组委员会。
Am J Gastroenterol. 1993 Jan;88(1):44-8.
5
[Recurrence-preventive (remission preserving) therapy of chronic inflammatory bowel diseases].[慢性炎症性肠病的预防复发（维持缓解）治疗]
Dtsch Med Wochenschr. 1998 Jan 23;123(4):85-7. doi: 10.1055/s-2007-1023902.
6
Standard immunosuppression in IBD: current practice.炎症性肠病的标准免疫抑制治疗：当前实践
Acta Gastroenterol Belg. 2001 Apr-Jun;64(2):182-8.
7
Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease.Rac1基因多态性与炎症性肠病患儿硫嘌呤类药物疗效的关系
J Pediatr Gastroenterol Nutr. 2015 Oct;61(4):404-7. doi: 10.1097/MPG.0000000000000820.
8
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.硫唑嘌呤、6-巯基嘌呤在炎症性肠病中的应用：药理学、疗效及安全性
Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43. doi: 10.1016/s1542-3565(04)00344-1.
9
Azathioprine, 6-mercaptopurine and thiopurine S-methyltransferase.硫唑嘌呤、6-巯基嘌呤与硫嘌呤甲基转移酶
J Gastroenterol Hepatol. 2005 Jun;20(6):955. doi: 10.1111/j.1440-1746.2005.03964.x.
10
Bone density improves with disease remission in patients with inflammatory bowel disease.炎症性肠病患者的骨密度会随着疾病缓解而改善。
Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1267-73. doi: 10.1097/00042737-200312000-00003.

引用本文的文献

1
Temporal Trends in Surgery and Hospitalization Rates for Crohn's Disease in Brazil: A Population-Based Study.巴西克罗恩病手术率和住院率的时间趋势：一项基于人群的研究。
Crohns Colitis 360. 2025 Jan 9;7(1):otae082. doi: 10.1093/crocol/otae082. eCollection 2025 Jan.
2
Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.低剂量巯嘌呤联合别嘌醇：这一有效组合的过去、现在与未来。
Dig Dis Sci. 2022 Dec;67(12):5382-5391. doi: 10.1007/s10620-022-07719-x. Epub 2022 Oct 15.
3
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.
炎症性肠病的常规治疗方法更新：5-氨基水杨酸、皮质类固醇、免疫调节剂和抗 TNF-α。
Korean J Intern Med. 2022 Sep;37(5):895-905. doi: 10.3904/kjim.2022.132. Epub 2022 Jul 27.
4
Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.经典药物在新药时代：1016 例炎症性肠病患者使用硫唑嘌呤单药治疗的真实世界、长期结局。
Aliment Pharmacol Ther. 2022 Sep;56(6):1030-1043. doi: 10.1111/apt.17128. Epub 2022 Jul 6.
5
Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?我们能否预测炎症性肠病患者对硫嘌呤类药物的毒性反应和疗效？
Front Med (Lausanne). 2019 Nov 28;6:279. doi: 10.3389/fmed.2019.00279. eCollection 2019.
6
Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants.炎症性肠病年轻患者中巯嘌呤的生物转化：谷胱甘肽 S-转移酶 M1 和 A1 变体的作用。
Genes (Basel). 2019 Apr 4;10(4):277. doi: 10.3390/genes10040277.
7
Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.戈利木单抗：英国两个三级炎症性肠病中心的早期经验和中期结果
Frontline Gastroenterol. 2018 Jul;9(3):221-231. doi: 10.1136/flgastro-2017-100895. Epub 2017 Oct 11.
8
What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?接受维得利珠单抗治疗的溃疡性结肠炎或克罗恩病患者发生进行性多灶性白质脑病的风险如何？
Inflamm Bowel Dis. 2018 Apr 23;24(5):953-959. doi: 10.1093/ibd/izx097.
9
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.维多珠单抗：迈向溃疡性结肠炎患者个性化治疗模式
Clin Exp Gastroenterol. 2017 Mar 3;10:57-66. doi: 10.2147/CEG.S110547. eCollection 2017.
10
Optimal management of steroid-dependent ulcerative colitis.类固醇依赖型溃疡性结肠炎的优化管理
Clin Exp Gastroenterol. 2015 Nov 12;8:293-302. doi: 10.2147/CEG.S57248. eCollection 2015.